SDShiva Dahal-Koirala

Shiva Dahal-Koirala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shiva Dahal-Koirala has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protocol for Non-viral HDR-based CRISPR/Cas9 platform for small custom editing in primary T cells

    by Katariina Mamia, Anniken Solveig Matheson Sollano, Shiva Dahal-Koirala, Emma Haapaniemi

    Summary: CRISPR/Cas9 enables precision gene editing via HDR for mutation correction and disease modelling. This protocol describes an 8-day non-viral HDR workflow for editing primary patient and healthy donor T cells, including reagent design, editing, on-target detection, and flow cytometry. The protocol was developed under research-grade conditions but supports scaling up and the transition to preclinical and clinical GMP workflows. For complete details on the use and execution of this protocol, please refer to Mamia et al.[1]. Before you begin: CRISPR/Cas9 gene editing is a promising tool to correct pathogenic variants for autologous cell therapies, targeting monogenic diseases such as inborn errors of immunity (IEI). Furthermore, it can be used as a tool for disease modelling to study normal and pathological variations of the immune system. Here we present a detailed protocol for an efficient and customizable T cell single nucleotide variant (SNV) correction platform based on homology-directed repair (HDR). The protocol details every step of the process, which starts with custom CRISPR/Cas9 reagent design of guide-RNAs (gRNAs) and repair templates for editing a novel target with no previously published reagents. Furthermore, we describe the strategy of reagent design to assess on-target HDR editing using droplet digital PCR (ddPCR). Next, we detail the T cell platform itself, and present effective strategies to stimulate PBMCs ex vivo to promote CD4+ and CD8+ T cell activation and proliferation, which we have validated in 32 unique IEI patients. Next, we present the workflow of gene editing T cells using nucleofection and CRISPR ribonucleoprotein (RNP) complexes for efficient editing that preserves high cell viabilities and up to 80% HDR. Finally, we present a flow cytometry panel that assesses the immune cells present at the end of the platform, including characterization of memory and effector T cell populations and status of T cell exhaustion. Innovation: In the study, we present a detailed protocol of performing highly efficient, non-viral and HDR-based precision editing in patient and healthy control T cells. The developed platform enables custom editing, such as correction of small pathogenic variants, with one workflow that we demonstrate to achieve up to 80% efficiency in multiple genomic loci and donors. Institutional permissions: The study was conducted in accordance with the principles of the Helsinki Declaration and approved by the Helsinki University Central Hospital Ethics Committee, and the Regional Committee for Medical and Health Research Ethics South-East Norway. All participants have signed written informed consent.

  • Open Access

    Editing of ADA2 Point Mutation in Human Hematopoietic Stem Cells

    by Pavel Kopcil, Carolina W. Ervik, Ganna Reint, Katariina Mamia, Monika Szymanska, Shiva Dahal-Koirala, Jacob Conradi, Sigrid Fu Skjelbostad, Oda A. Dønåsen, Xiaojun Jiang, et al.

    Background: The homozygous ADA2 : c.506G>A (p.Arg169Gln; p.R169Q) variant accounts for majority of Deficiency in Adenosine Deaminase 2 (DADA2). This monogenic disorder may be amenable to ex vivo gene therapy by correcting the pathogenic mutation in CD34+ hematopoietic stem and progenitor cells (HSPCs). Objective: To apply CRISPR-Cas9 and homology-directed repair (HDR) as a surrogate strategy to model correction of the pathogenic ADA2 c.506G>A variant in healthy cord blood HSPCs. Methods: HSPCs were electroporated with optimised CRISPR-Cas9 editing reagents, and editing outcomes, including HDR and on-target deletions, were quantified by ddPCR. Cell functionality was assessed through colony-forming unit (CFU) assays and by xenotransplantation into NOD SCID Gamma (NSG) mice. Two HDR enhancement strategies were tested: (1) genetic inhibitors of p53 and non-homologous end joining (NHEJ) pathways, and (2) pharmacological NHEJ inhibition. Results: Small-molecule NHEJ inhibitors increased HDR efficiency approximately two-fold (from ∼40 % to ∼80 %). Edited HSPCs retained normal CFU capacity and successfully engrafted in NSG mice. However, up to 8 % of edited cells exhibited on-target chromosome loss, though this declined over time. Up to 40 % of T cells and fibroblasts demonstrated similar losses under NHEJ inhibitors treatment. In contrast, genetically encoded inhibitors did not improve HDR. Conclusion: The ADA2 p. c.506G>A variant can be effectively edited employing surrogate strategy in HSPCs without impairing functionality. Although pharmacological inhibition of NHEJ enhances HDR efficiency, it also increases the risk of on-target chromosome aberrations, highlighting the need for careful consideration of the associated risks and benefits in therapeutic gene editing. Key messages: 1) The ADA2 p.R169Q variant can be efficiently corrected via HDR, and the edited CD34+ HSPCs retain their engraftment capability in NSG mice. 2) Pharmacological inhibition of NHEJ using small-molecule inhibitors increases HDR efficiency but is associated with significant on-target deletions and chromosomal arm loss, particularly in differentiated cell types, and in a donor-dependent manner. Capsule summary: The ADA2 p.R169Q variant is a viable target for precision gene editing in hematopoietic stem cells. Although inhibition of NHEJ improves HDR efficiency, it concomitantly increases the risk of large on-target deletions, particularly in differentiated cells.

  • Open Access

    A predisposing effect of HLA class II genes in celiac disease by skewing the naïve CD4 + T-cell receptor repertoire

    by Ida Lindeman, Aengus Officer, Shiva Dahal-Koirala, Louise F. Risnes, Rebecka Hjort, Knut E. A. Lundin, Eivind Ness-Jensen, Corey T. Watson, Ludvig M. Sollid

    Polymorphisms of human leukocyte antigen (HLA) genes confer risks for many human diseases. For predisposing effects relating to T-cell receptor (TCR) recognition of peptide-HLA, the effect can be both selection of the TCR repertoire and preferential presentation of disease-driving epitopes. In celiac disease (CeD) HLA-DQ2.5 predisposes by presenting deamidated gluten peptides to CD4 + T cells that typically employ stereotyped TCRs. Here we analyzed whether genetic variants within the HLA and TR loci shape the naïve TCR repertoire. We sequenced the αβ TCR repertoires of naïve CD4 + T cells of 103 CeD subjects and 103 controls and performed gene usage quantitative trait loci analyses. The naïve CD4 + TCR repertoire was significantly affected by HLA and TRA and TRB polymorphisms. Individuals carrying the HLA-DQ2.5 allotype exhibited increased frequencies of TCR genes involved in stereotyped recognition of gluten epitopes thus demonstrating a disease-predisposing effect of HLA by selection of a disease-relevant TCR repertoire.

  • Identification of gluten T cell epitopes driving celiac disease

    by Markéta Chlubnová, Asbjørn O. Christophersen, Geir Kjetil F. Sandve, Knut E.A Lundin, Jørgen Jahnsen, Shiva Dahal-Koirala, Ludvig M. Sollid

    CD4 + T cells specific for cereal gluten proteins are key players in celiac disease (CeD) pathogenesis. While several CeD-relevant gluten T cell epitopes have been identified, epitopes recognized by a substantial proportion of gluten-reactive T cells remain unknown. The identification of such CeD-driving gluten epitopes is important for the food industry and in clinical settings. Here, we have combined the knowledge of a distinct phenotype of gluten-reactive T cells and key features of known gluten epitopes for the discovery of unknown epitopes. We tested 42 wheat gluten–reactive T cell clones, isolated on the basis of their distinct phenotype and with no reactivity to known epitopes, against a panel of synthetic peptides bioinformatically identified from a wheat gluten protein database. We were able to assign reactivity to 10 T cell clones and identified a 9-nucleotide oligomer core region of five previously uncharacterized gliadin/glutenin epitopes. This work represents an advance in the effort to identify CeD-driving gluten epitopes.


  • Open Access

    Phenotype‐Based Isolation of Antigen‐Specific CD4+ T Cells in Autoimmunity: A Study of Celiac Disease

    by Asbjørn Christophersen, Shiva Dahal‐Koirala, Markéta Chlubnová, Jørgen Jahnsen, Knut E. A. Lundin, Ludvig M. Sollid

    The pathogenic immune response in celiac disease (CeD) is orchestrated by phenotypically distinct CD4+ T cells that recognize gluten epitopes in the context of disease‐associated HLA‐DQ allotypes. Cells with the same distinct phenotype, but with elusive specificities, are increased across multiple autoimmune conditions. Here, whether sorting of T cells based on their distinct phenotype (Tphe cells) yields gluten‐reactive cells in CeD is tested. The method′s efficiency is benchmarked by parallel isolation of gluten‐reactive T cells (Ttet cells), using HLA‐DQ:gluten peptide tetramers. From gut biopsies of 12 untreated HLA‐DQ2.5+ CeD patients, Ttet+/Tphe+, Ttet−/Tphe+, and Ttet−/Tphe− cells are sorted for single‐cell T‐cell receptor (TCR)‐sequencing (n = 8) and T‐cell clone (TCC)‐generation (n = 5). The generated TCCs are TCR sequenced and tested for their reactivity against deamidated gluten. Gluten‐reactivity is observed in 91.2% of Ttet+/Tphe+ TCCs, 65.3% of Ttet−/Tphe+ TCCs and 0% of Ttet−/Tphe− TCCs. TCR sequencing reveals clonal expansion and sequence sharing across patients, features reflecting antigen‐driven responses. The feasibility to isolate antigen‐specific CD4+ T cells by the sole use of phenotypic markers in CeD outlines a potential avenue for characterizing disease‐driving CD4+ T cells in autoimmune conditions.


  • Open Access

    Antibodies to native gluten arise from cross-reactive B cells with implications for epitope spreading in celiac disease

    by Chunyan Zhou, Thomas Østerbye, Shiva Dahal-Koirala, Øyvind Steinsbø, Jørgen Jahnsen, Knut E. A. Lundin, Søren Buus, Ludvig M. Sollid, Rasmus Iversen

    Antibodies to deamidated gluten peptides are accurate diagnostic markers of celiac disease (CeD). However, antibody binding to all possible gluten epitopes has not previously been investigated. To map antibody reactivity in detail and to understand the connection between disease-relevant B-cell and T-cell epitopes, we took advantage of a high-density peptide array for assessment of serum antibody specificity in CeD across the wheat gluten proteome. We confirm the importance of peptide deamidation for antibody binding, and we show that the response is remarkably focused on the known epitope QPEQPFP (where E results from deamidation of Q). In addition, we describe a new epitope in native (non-deamidated) gluten, QQPEQII (where E is gene encoded), which was associated with both B-cell and T-cell reactivity. By generating monoclonal antibodies from peptide-binding gut plasma cells of CeD patients, we show that antibodies to this native gluten epitope are cross-reactive with the major deamidated epitope due to recognition of the shared PEQ motif. Hence, antibodies to native gluten appear to arise from cross-reactive B cells that are generated as a side effect of the immune response to deamidated gluten. Since cross-reactive B cells could present peptides to different gluten-specific T cells, we suspect that such B cells can play a role in epitope spreading by engaging T cells with multiple specificities.

  • Open Access

    TCRpower: quantifying the detection power of T-cell receptor sequencing with a novel computational pipeline calibrated by spike-in sequences

    by Shiva Dahal-Koirala, Gabriel Balaban, Ralf Stefan Neumann, Lonneke Scheffer, Knut Erik Aslaksen Lundin, Victor Greiff, Ludvig Magne Sollid, Shuo-Wang Qiao, Geir Kjetil Sandve

    T-cell receptor (TCR) sequencing has enabled the development of innovative diagnostic tests for cancers, autoimmune diseases and other applications. However, the rarity of many T-cell clonotypes presents a detection challenge, which may lead to misdiagnosis if diagnostically relevant TCRs remain undetected. To address this issue, we developed TCRpower, a novel computational pipeline for quantifying the statistical detection power of TCR sequencing methods. TCRpower calculates the probability of detecting a TCR sequence as a function of several key parameters: in-vivo TCR frequency, T-cell sample count, read sequencing depth and read cutoff. To calibrate TCRpower, we selected unique TCRs of 45 T-cell clones (TCCs) as spike-in TCRs. We sequenced the spike-in TCRs from TCCs, together with TCRs from peripheral blood, using a 5′ RACE protocol. The 45 spike-in TCRs covered a wide range of sample frequencies, ranging from 5 per 100 to 1 per 1 million. The resulting spike-in TCR read counts and ground truth frequencies allowed us to calibrate TCRpower. In our TCR sequencing data, we observed a consistent linear relationship between sample and sequencing read frequencies. We were also able to reliably detect spike-in TCRs with frequencies as low as one per million. By implementing an optimized read cutoff, we eliminated most of the falsely detected sequences in our data (TCR α-chain 99.0% and TCR β-chain 92.4%), thereby improving diagnostic specificity. TCRpower is publicly available and can be used to optimize future TCR sequencing experiments, and thereby enable reliable detection of disease-relevant TCRs for diagnostic applications.


  • Open Access

    Structural basis of T cell receptor specificity and cross-reactivity of two HLA-DQ2.5-restricted gluten epitopes in celiac disease

    by Laura Ciacchi, Carine Farenc, Shiva Dahal-Koirala, Jan Petersen, Ludvig M. Sollid, Hugh H. Reid, Jamie Rossjohn


  • Contributors

    by Daniel Agardh, Julie Antvorskov, Federico Biagi, Margit Brottveit, Antonio Carroccio, Ashish Chauhan, Carolina Ciacci, Jette Frederiksen, Marios Hadjivassiliou, Kaisa Hervonen, et al.

  • A molecular basis for the T cell response in HLA-DQ2.2 mediated celiac disease

    by Yi Tian Ting, Shiva Dahal-Koirala, Hui Shi Keshia Kim, Shuo-Wang Qiao, Ralf S. Neumann, Knut E. A. Lundin, Jan Petersen, Hugh H. Reid, Ludvig M. Sollid, Jamie Rossjohn

    The highly homologous human leukocyte antigen (HLA)-DQ2 molecules, HLA-DQ2.5 and HLA-DQ2.2, are implicated in the pathogenesis of celiac disease (CeD) by presenting gluten peptides to CD4+T cells. However, while HLA-DQ2.5 is strongly associated with disease, HLA-DQ2.2 is not, and the molecular basis underpinning this differential disease association is unresolved. We here provide structural evidence for how the single polymorphic residue (HLA-DQ2.5-Tyr22α and HLA-DQ2.2-Phe22α) accounts for HLA-DQ2.2 additionally requiring gluten epitopes possessing a serine at the P3 position of the peptide. In marked contrast to the biased T cell receptor (TCR) usage associated with HLA-DQ2.5–mediated CeD, we demonstrate with extensive single-cell sequencing that a diverse TCR repertoire enables recognition of the immunodominant HLA-DQ2.2-glut-L1 epitope. The crystal structure of two CeD patient-derived TCR in complex with HLA-DQ2.2 and DQ2.2-glut-L1 (PFSEQEQPV) revealed a docking strategy, and associated interatomic contacts, which was notably distinct from the structures of the TCR:HLA-DQ2.5:gliadin epitope complexes. Accordingly, while the molecular surfaces of the antigen-binding clefts of HLA-DQ2.5 and HLA-DQ2.2 are very similar, differences in the nature of the peptides presented translates to differences in responding T cell repertoires and the nature of engagement of the respective antigen-presenting molecules, which ultimately is associated with differing disease penetrance.